Evoke Pharma Stock Performance
| EVOK Stock | USD 0.49 0.03 6.52% |
The firm shows a Beta (market volatility) of -0.46, which means possible diversification benefits within a given portfolio. As returns on the market increase, returns on owning Evoke Pharma are expected to decrease at a much lower rate. During the bear market, Evoke Pharma is likely to outperform the market. Evoke Pharma has an expected return of -0.37%. Please make sure to confirm Evoke Pharma potential upside, as well as the relationship between the rate of daily change and relative strength index , to decide if Evoke Pharma performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Evoke Pharma has generated negative risk-adjusted returns adding no value to investors with long positions. Despite inconsistent performance in the last few months, the Stock's basic indicators remain quite persistent which may send shares a bit higher in June 2024. The latest mess may also be a sign of long-standing up-swing for the company institutional investors. ...more
Last Split Factor 1:12 | Last Split Date 2022-05-23 |
1 | Evoke Pharma down 28, prices 30M offering | 02/09/2024 |
2 | Evoke Pharma Earns Sell Rating from Analysts at StockNews.com - AmericanBankingNEWS | 03/01/2024 |
3 | Evoke Pharma Coverage Initiated at StockNews.com - Defense World | 03/08/2024 |
4 | Evoke Pharma Reports Fourth Quarter and Full Year 2023 Financial Results | 03/14/2024 |
5 | EVOK Stock Earnings Evoke Pharma Misses EPS, Beats Revenue for Q4 2023 | 03/15/2024 |
6 | Evoke Pharma names Matthew DOnofrio as new CEO | 03/21/2024 |
7 | EVOKE PHARMA INC. Revenue Breakdown SWBEV00 TradingView - TradingView | 03/28/2024 |
8 | EVOKE PHARMA INC.DL-,0001 Revenue Breakdown MUNEV00 TradingView - TradingView | 04/04/2024 |
9 | Evoke Pharma to Host Virtual Key Opinion Leader Webinar on the Evolving Landscape of Gastroparesis GIMOTI, Hospitalizations, and GLP-1 Medications | 04/17/2024 |
10 | StockNews.com Initiates Coverage on Evoke Pharma - Defense World | 04/26/2024 |
| Begin Period Cash Flow | 9.8 M |
Evoke |
Evoke Pharma Relative Risk vs. Return Landscape
If you would invest 68.00 in Evoke Pharma on February 4, 2024 and sell it today you would lose (19.00) from holding Evoke Pharma or give up 27.94% of portfolio value over 90 days. Evoke Pharma is currently does not generate positive expected returns and assumes 5.5002% risk (volatility on return distribution) over the 90 days horizon. In different words, 48% of stocks are less volatile than Evoke, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Evoke Pharma Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Evoke Pharma's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Evoke Pharma, and traders can use it to determine the average amount a Evoke Pharma's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0678
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | EVOK |
Estimated Market Risk
| 5.5 actual daily | 48 52% of assets are more volatile |
Expected Return
| -0.37 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.07 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Evoke Pharma is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Evoke Pharma by adding Evoke Pharma to a well-diversified portfolio.
Evoke Pharma Fundamentals Growth
Evoke Stock prices reflect investors' perceptions of the future prospects and financial health of Evoke Pharma, and Evoke Pharma fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Evoke Stock performance.
| Return On Equity | -10.35 | ||||
| Return On Asset | -0.49 | ||||
| Profit Margin | (1.50) % | ||||
| Operating Margin | (1.13) % | ||||
| Current Valuation | 4.14 M | ||||
| Shares Outstanding | 8.48 M | ||||
| Price To Earning | (3.21) X | ||||
| Price To Book | 1.79 X | ||||
| Price To Sales | 0.83 X | ||||
| Revenue | 5.18 M | ||||
| Gross Profit | 2.14 M | ||||
| EBITDA | (7.43 M) | ||||
| Net Income | (7.79 M) | ||||
| Cash And Equivalents | 13.45 M | ||||
| Cash Per Share | 4.02 X | ||||
| Total Debt | 5 M | ||||
| Debt To Equity | 0.69 % | ||||
| Current Ratio | 10.65 X | ||||
| Book Value Per Share | (0.77) X | ||||
| Cash Flow From Operations | (4.98 M) | ||||
| Earnings Per Share | (2.33) X | ||||
| Market Capitalization | 3.88 M | ||||
| Total Asset | 7.07 M | ||||
| Retained Earnings | (123.44 M) | ||||
| Working Capital | 3.79 M | ||||
| Current Asset | 9.52 M | ||||
| Current Liabilities | 1.83 M | ||||
About Evoke Pharma Performance
To evaluate Evoke Pharma Stock as a possible investment, you need to clearly understand its upside potential, downside risk, and overall future performance outlook. You may be satisfied when Evoke Pharma generates a 15% return over the last few months, but what if the market is generating 25% over the same period? In this case, it makes sense to compare Evoke Stock's performance with different market indexes, such as the Dow or NASDAQ Composite. These indexes can act as benchmarks that will help you to understand Evoke Pharma market performance in a much more refined way. The Macroaxis performance score is an integer between 0 and 100 that represents Evoke's market performance from a risk-adjusted return perspective. Generally speaking, the higher the score, the better is overall performance as compared to other investors. The score is normalized against the average investing universe (the best we can interpret from the data available). Within this methodology, scores of individual equity instruments will always be inferior to the scores of portfolios of equities as portfolios typically diversify a lot of unsystematic risks away. The formula to derive the Macroaxis score bases on multiple unequally-weighted factors. For more information, refer to our portfolio performance evaluation section.
Please also refer to our technical analysis and fundamental analysis pages.| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 871.17 | 648.49 | |
| Return On Tangible Assets | (1.10) | (1.16) | |
| Return On Capital Employed | (1.84) | (1.93) | |
| Return On Assets | (1.10) | (1.16) | |
| Return On Equity | 3.02 | 3.17 |
Things to note about Evoke Pharma performance evaluation
Checking the ongoing alerts about Evoke Pharma for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Evoke Pharma help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Evoke Pharma generated a negative expected return over the last 90 days | |
| Evoke Pharma has high historical volatility and very poor performance | |
| Evoke Pharma has some characteristics of a very speculative penny stock | |
| Evoke Pharma has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 5.18 M. Net Loss for the year was (7.79 M) with profit before overhead, payroll, taxes, and interest of 2.14 M. | |
| Evoke Pharma currently holds about 13.45 M in cash with (4.98 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.02, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Evoke Pharma has a poor financial position based on the latest SEC disclosures | |
| Latest headline from news.google.com: StockNews.com Initiates Coverage on Evoke Pharma - Defense World |
- Analyzing Evoke Pharma's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Evoke Pharma's stock is overvalued or undervalued compared to its peers.
- Examining Evoke Pharma's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Evoke Pharma's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Evoke Pharma's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Evoke Pharma's stock. These opinions can provide insight into Evoke Pharma's potential for growth and whether the stock is currently undervalued or overvalued.
Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Evoke Pharma. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in persons. For more information on how to buy Evoke Stock please use our How to buy in Evoke Stock guide.You can also try the Sign In To Macroaxis module to sign in to explore Macroaxis' wealth optimization platform and fintech modules.
Complementary Tools for Evoke Stock analysis
When running Evoke Pharma's price analysis, check to measure Evoke Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Evoke Pharma is operating at the current time. Most of Evoke Pharma's value examination focuses on studying past and present price action to predict the probability of Evoke Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Evoke Pharma's price. Additionally, you may evaluate how the addition of Evoke Pharma to your portfolios can decrease your overall portfolio volatility.
| Global Correlations Find global opportunities by holding instruments from different markets | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. |
Is Evoke Pharma's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Evoke Pharma. If investors know Evoke will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Evoke Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.33) | Revenue Per Share 1.55 | Quarterly Revenue Growth 1.105 | Return On Assets (0.49) | Return On Equity (10.35) |
The market value of Evoke Pharma is measured differently than its book value, which is the value of Evoke that is recorded on the company's balance sheet. Investors also form their own opinion of Evoke Pharma's value that differs from its market value or its book value, called intrinsic value, which is Evoke Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Evoke Pharma's market value can be influenced by many factors that don't directly affect Evoke Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Evoke Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Evoke Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Evoke Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.